XBIT
XBiotech Inc.
Biotechnology
Market Cap$76M
5Y Perf.-82.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
XBIT vs ARQT
Revenue, margins, valuation, and 5-year total return — side by side.
ARQT
Arcutis Biotherapeutics, Inc.
Biotechnology
Market Cap$2.58B
5Y Perf.-38.4%
XBIT vs ARQT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | XBIT | ARQT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $76M | $2.58B |
| Revenue (TTM) | $0.00 | $416M |
| Net Income (TTM) | $-29M | $-2M |
| Gross Margin | — | 90.9% |
| Operating Margin | — | 0.8% |
| Forward P/E | — | 77.6x |
| Total Debt | $10M | $6M |
| Cash & Equiv. | $173M | $43M |
XBIT vs ARQT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
XBIT
ARQT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| XBiotech Inc. (XBIT) | 100 | 17.9 | -82.1% |
| Arcutis Biotherapeu… (ARQT) | 100 | 61.6 | -38.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: XBIT vs ARQT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ARQT leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. XBiotech Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
XBIT
XBiotech Inc.
The Income Pick
XBIT is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 1.21
- Lower volatility, beta 1.21, Low D/E 5.6%, current ratio 11.56x
- Beta 1.21, current ratio 11.56x
Best for: income & stability and sleep-well-at-night
ARQT
Arcutis Biotherapeutics, Inc.
The Growth Play
ARQT carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 91.3%, EPS growth 88.8%, 3Y rev CAGR 367.3%
- -5.2% 10Y total return vs XBIT's -60.2%
- 91.3% revenue growth vs XBIT's 11.3%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ARQT | 91.3% revenue growth vs XBIT's 11.3% |
| Quality / Margins | XBIT | 4.5% margin vs ARQT's -0.6% |
| Stability / Safety | XBIT | Beta 1.21 vs ARQT's 1.48 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ARQT | +50.8% vs XBIT's -10.4% |
| Efficiency (ROA) | ARQT | -0.6% ROA vs XBIT's -16.9%, ROIC -5.2% vs -164.8% |
XBIT vs ARQT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2022
FY 2023
XBIT vs ARQT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLARQTLAGGINGXBIT
XBITXBiotech Inc.
1leads
ARQTArcutis Biotherapeuti…
3leads
6 Total Categories
CATEGORYLEADERvs XBITMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ARQT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ARQT8/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ARQT5/6
Risk & VolatilityBeta, volatility, and downside exposure
XBIT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ARQT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ARQT and XBIT operate at a comparable scale, with $416M and $0 in trailing revenue.
| Metric | XBITXBiotech Inc. | ARQTArcutis Biotherap… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $416M |
| EBITDAEarnings before interest/tax | -$33M | $6M |
| Net IncomeAfter-tax profit | -$29M | -$2M |
| Free Cash FlowCash after capex | -$24M | $27M |
| Gross MarginGross profit ÷ Revenue | — | +90.9% |
| Operating MarginEBIT ÷ Revenue | — | +0.8% |
| Net MarginNet income ÷ Revenue | — | -0.6% |
| FCF MarginFCF ÷ Revenue | — | +6.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +60.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -25.0% | +55.0% |
ARQT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — XBIT and ARQT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | XBITXBiotech Inc. | ARQTArcutis Biotherap… |
|---|---|---|
| Market CapShares × price | $76M | $2.6B |
| Enterprise ValueMkt cap + debt − cash | -$86M | $2.5B |
| Trailing P/EPrice ÷ TTM EPS | -1.98x | -158.92x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 77.64x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 6.87x |
| Price / BookPrice ÷ Book value/share | 0.42x | 13.87x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — XBIT and ARQT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
ARQT leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
ARQT delivers a -1.4% return on equity — every $100 of shareholder capital generates $-1 in annual profit, vs $-17 for XBIT. ARQT carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to XBIT's 0.06x. On the Piotroski fundamental quality scale (0–9), ARQT scores 4/9 vs XBIT's 2/9, reflecting mixed financial health.
| Metric | XBITXBiotech Inc. | ARQTArcutis Biotherap… |
|---|---|---|
| ROE (TTM)Return on equity | -17.5% | -1.4% |
| ROA (TTM)Return on assets | -16.9% | -0.6% |
| ROICReturn on invested capital | -164.8% | -5.2% |
| ROCEReturn on capital employed | -21.0% | -4.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 0.06x | 0.03x |
| Net DebtTotal debt minus cash | -$162M | -$37M |
| Cash & Equiv.Liquid assets | $173M | $43M |
| Total DebtShort + long-term debt | $10M | $6M |
| Interest CoverageEBIT ÷ Interest expense | -98.45x | 2.08x |
ARQT leads this category, winning 8 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ARQT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ARQT five years ago would be worth $6,053 today (with dividends reinvested), compared to $2,917 for XBIT. Over the past 12 months, ARQT leads with a +50.8% total return vs XBIT's -10.4%. The 3-year compound annual growth rate (CAGR) favors ARQT at 13.2% vs XBIT's -8.7% — a key indicator of consistent wealth creation.
| Metric | XBITXBiotech Inc. | ARQTArcutis Biotherap… |
|---|---|---|
| YTD ReturnYear-to-date | +5.0% | -28.8% |
| 1-Year ReturnPast 12 months | -10.4% | +50.8% |
| 3-Year ReturnCumulative with dividends | -24.0% | +44.9% |
| 5-Year ReturnCumulative with dividends | -70.8% | -39.5% |
| 10-Year ReturnCumulative with dividends | -60.2% | -5.2% |
| CAGR (3Y)Annualised 3-year return | -8.7% | +13.2% |
ARQT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
XBIT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
XBIT is the less volatile stock with a 1.21 beta — it tends to amplify market swings less than ARQT's 1.48 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XBIT currently trades 69.3% from its 52-week high vs ARQT's 65.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | XBITXBiotech Inc. | ARQTArcutis Biotherap… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.21x | 1.48x |
| 52-Week HighHighest price in past year | $3.61 | $31.77 |
| 52-Week LowLowest price in past year | $2.09 | $12.42 |
| % of 52W HighCurrent price vs 52-week peak | +69.3% | +65.0% |
| RSI (14)Momentum oscillator 0–100 | 61.8 | 54.3 |
| Avg Volume (50D)Average daily shares traded | 36K | 1.3M |
XBIT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | XBITXBiotech Inc. | ARQTArcutis Biotherap… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $35.50 |
| # AnalystsCovering analysts | — | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ARQT leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). XBIT leads in 1 (Risk & Volatility). 1 tied.
Best OverallArcutis Biotherapeutics, In… (ARQT)Leads 3 of 6 categories
Loading custom metrics...
XBIT vs ARQT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is XBIT or ARQT a better buy right now?
Analysts rate Arcutis Biotherapeutics, Inc.
(ARQT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — XBIT or ARQT?
Over the past 5 years, Arcutis Biotherapeutics, Inc.
(ARQT) delivered a total return of -39. 5%, compared to -70. 8% for XBiotech Inc. (XBIT). Over 10 years, the gap is even starker: ARQT returned -5. 2% versus XBIT's -60. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — XBIT or ARQT?
By beta (market sensitivity over 5 years), XBiotech Inc.
(XBIT) is the lower-risk stock at 1. 21β versus Arcutis Biotherapeutics, Inc. 's 1. 48β — meaning ARQT is approximately 22% more volatile than XBIT relative to the S&P 500. On balance sheet safety, Arcutis Biotherapeutics, Inc. (ARQT) carries a lower debt/equity ratio of 3% versus 6% for XBiotech Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — XBIT or ARQT?
On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc.
grew EPS 88. 8% year-over-year, compared to -55. 6% for XBiotech Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — XBIT or ARQT?
XBiotech Inc.
(XBIT) is the more profitable company, earning 0. 0% net margin versus -4. 3% for Arcutis Biotherapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XBIT leads at 0. 0% versus -3. 3% for ARQT. At the gross margin level — before operating expenses — ARQT leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — XBIT or ARQT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is XBIT or ARQT better for a retirement portfolio?
For long-horizon retirement investors, XBiotech Inc.
(XBIT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 21)). Both have compounded well over 10 years (XBIT: -60. 2%, ARQT: -5. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between XBIT and ARQT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: XBIT is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.